David D. Ho, M.D., Scientific Director & CEO, Aaron Diamond AIDS Research Center
David Ho has been at the forefront of AIDS research for 30 years, publishing over 350 papers. His elegant studies, beginning in 1994, unveiled the dynamic nature of HIV replication in vivo and revolutionized our basic understanding of this horrific disease. AIDS mortality in richer nations has declined 7-fold since 1996, and a massive international effort is now underway to bring such life-saving treatment to millions in the developing world. Dr. Ho was named TIME magazine’s Man of the Year in 1996, and was the recipient of a Presidential Medal in 2001.
Chris Dagdigian, Founding Partner and Director, Technology, BioTeam, Inc.
Formerly of Blackstone Computing and Genetics Institute, Chris Dagdigian specializes in research computing and infrastructure technology issues in the life sciences. A supporter of free software and open standards for life science research, he is a founding member of the Bioperl Project. Dagdigian was project manager and technical lead for the creation and integration of the Vertex Pharmaceutical VAMPIRE cluster, which replaced an existing Top500 supercomputer used for cutting edge discovery research and informatics.
Yaron Turpaz, Ph.D., Vice President, Informatics & Information Sciences, Research & Development Information, AstraZeneca Plc.
Previously the Director of Integrative Computational Sciences at Lilly Singapore Centre for Drug Discovery and Co-founded the Asian Cancer Research Group (ACRG) with Eli Lilly, Merck and Pfizer, Yaron Turpaz is Vice President of Informatics & Information Sciences, R&D Information at AstraZeneca Plc. He leads global teams of Discovery Informatics, Clinical Informatics, Knowledge Engineering and Scientific Information Services. Yaron also leads the establishment of R&D Information Hubs in Emerging Markets such as Asia and Russia.
Peter Little, Ph.D., Professor, Associate Director, Singapore Centre on Life Sciences Engineering; Director, Life Sciences Institute; Research Director, Office of Deputy President (Research & Technology), National University of Singapore
Peter Little is Director of the Life Sciences Institute and Research Director in the NUS Office of Prof Barry Halliwell, Deputy President (Research and Technology) where they together lead the NUS Virtual institute for the Study of Aging. He is a founding member of the Singapore Centre on Environmatal Life Sciences Engineering (SCELSE), a SGD250 million research centre of excellence researching on bacterial biofilms and communities.
Moderator: Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World
Kevin Davies is the Editor-in-Chief of Bio-IT World, the founding editor of Nature Genetics, and the author of three books, most recently "The $1,000 Genome" (published by Free Press in 2010). Kevin has spent two decades in science publishing, having completed postdoctoral fellowships at MIT and Harvard Medical School.
Yoshihide Hayashizaki, M.D., Ph.D., Director, RIKEN Omics Science Center
Since appointed as the Project Director for the RIKEN Genome Project in 1995, Dr. Hayashizaki has taken a transversal data-driven approach to analyze transcriptomes by developing unique technologies including a series of cDNA technologies. With this approach, he has established a of full-length cDNA clone bank. This activity was followed by organization of FANTOM (Functional Annotation of Mammalian Genome), an international consortium, originally to annotate a large number of cDNA and subsequently expanded to transcriptome and network analysis.
Seong-Jin Kim, Ph.D., President, CHA Research Institutes; Director, CHA Cancer Institute; Distinguished Professor, CHA University.
Dr. Seong-Jin Kim is the donor of the first Korean genome (SJK). He led the Korean Genome Sequencing project when he was the Director of the Lee Gil Ya Cancer and Diabetes Institute, South Korea in 2008. Dr. Kim worked as a senior investigator at the Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, NIH. His research interests included the molecular basis for altered TGF-beta signaling in various human diseases including cancer. Dr. Kim received many outstanding awards such as HoAm Prize in Medicine, and he is regarded one of the most influential researchers in cancer and personalized medicine research in Korea.